Problem: Unresolved production incidents often accumulate into backlogs of 50–100 open cases, with many pending for over 90 days. These backlogs strain investigation teams and force senior management to spend up to 40% of their time on incident closures rather than production improvements. Left unaddressed, these pending incidents normalise inefficiency, delay batch releases, and cause significant revenue loss through supply chain disruptions. Solution: The approach involves a two-pronged strategy: streamlining BPRs using ALCOA+ principles to reduce documentation load by 25% and implementing a Supervisor Span Framework. Additionally, it introduces structured investigation templates and a common priority system to accelerate the closure of existing backlogs. Benefits: These GMP-aligned changes can reduce documentation-related human errors by 60%–70% and cut incident closure timelines by 30%–40%. Ultimately, this transforms operations from reactive firefighting to a high-performance environment with faster batch releases and improved supply chain reliability.

Key takeaways

High incident backlogs strain pharma plants. By streamlining BPRs and using structured investigation templates, sites can reduce errors by 70% and speed up closures by 40%, ensuring faster batch releases and compliance.

From errors to excellence. A GMP-aligned approach to reducing incidents

From errors to excellence. A GMP-aligned approach to reducing incidents

Download PDF

Eliminate pharmaceutical production backlogs. Learn how streamlining BPRs and optimising supervisor spans can reduce human error by 70% and speed up incident closures by 40% for faster batch releases.